ENGN Insider Trading

Insider Ownership Percentage: 13.70%
Insider Buying (Last 12 Months): $2,761,601.60
Insider Selling (Last 12 Months): $786,480.75

enGene Insider Trading History Chart

This chart shows the insider buying and selling history at enGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

enGene Share Price & Price History

Current Price: $8.09
Price Change: Price Decrease of -0.56 (-6.47%)
As of 12/9/2024 01:00 AM ET

This chart shows the closing price history over time for ENGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

enGene Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2024Growth Opportunities F ForbionMajor ShareholderBuy11,844$6.55$77,578.202,469,833View SEC Filing Icon  
10/4/2024Growth Opportunities F ForbionMajor ShareholderBuy5,997$6.54$39,220.382,457,989View SEC Filing Icon  
10/2/2024Growth Opportunities F ForbionMajor ShareholderBuy10,153$6.37$64,674.612,446,223View SEC Filing Icon  
9/30/2024Growth Opportunities F ForbionMajor ShareholderBuy341,332$6.34$2,164,044.882,400,791View SEC Filing Icon  
9/27/2024Growth Opportunities F ForbionMajor ShareholderBuy41,639$5.97$248,584.832,059,459View SEC Filing Icon  
9/27/2024Ronald Harold Wilfred CooperCEOBuy10,000$5.70$57,000.0010,000View SEC Filing Icon  
4/22/2024De Solidarite Des Travai FondsMajor ShareholderSell47,854$15.00$717,810.003,036,153View SEC Filing Icon  
4/18/2024De Solidarite Des Travai FondsMajor ShareholderSell4,575$15.01$68,670.753,084,107View SEC Filing Icon  
12/29/2023Growth Opportunities F ForbionMajor ShareholderBuy10,020$9.06$90,781.202,017,820View SEC Filing Icon  
12/27/2023Growth Opportunities F ForbionMajor ShareholderBuy2,750$7.17$19,717.502,002,750View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for enGene (NASDAQ:ENGN)

64.16% of enGene stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ENGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

enGene Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/27/2024Franklin Resources Inc.1,189,952$7.85M0.0%+48.7%2.691%Search for SEC Filing on Google Icon
11/15/2024Point72 Asset Management L.P.663,000$4.38M0.0%+1,410.3%1.499%Search for SEC Filing on Google Icon
11/4/2024Wolverine Asset Management LLC5,574$37K0.0%N/A0.013%Search for SEC Filing on Google Icon
8/19/2024Point72 Asset Management L.P.43,900$0.41M0.0%-76.0%0.099%Search for SEC Filing on Google Icon
8/16/2024Perceptive Advisors LLC800,000$7.54M0.2%-19.9%1.811%Search for SEC Filing on Google Icon
8/15/2024Blue Owl Capital Holdings LP2,449,827$23.10M6.4%-0.5%5.547%Search for SEC Filing on Google Icon
8/14/2024Marshall Wace LLP764,645$7.21M0.0%-4.4%1.731%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP1,200,000$11.32M0.9%+50.0%2.717%Search for SEC Filing on Google Icon
8/13/2024SR One Capital Management LP500,000$4.72M1.5%N/A1.132%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC1,000,000$17.10M0.0%N/A2.295%Search for SEC Filing on Google Icon
5/15/2024Altitude Crest Partners Inc.120,289$2.04M0.9%N/A0.276%Search for SEC Filing on Google Icon
3/7/2024Fcpm Iii Services B.V.8,677,951$80.10M23.8%N/A37.408%Search for SEC Filing on Google Icon
2/15/2024Omega Fund Management LLC1,131,175$10.44M8.5%N/A4.876%Search for SEC Filing on Google Icon
2/15/2024BVF Inc. IL2,251,037$20.78M0.5%N/A9.703%Search for SEC Filing on Google Icon
2/7/2024Vivo Capital LLC678,705$6.26M0.5%N/A2.925%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
enGene logo
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More on enGene

Today's Range

Now: $8.09
Low: $8.09
High: $8.65

50 Day Range

MA: $8.15
Low: $6.46
High: $9.83

52 Week Range

Now: $8.09
Low: $4.42
High: $18.40

Volume

33,391 shs

Average Volume

115,704 shs

Market Capitalization

$357.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of enGene?

enGene's top insider investors include:
  1. De Solidarite Des Travai Fonds (Major Shareholder)
  2. Growth Opportunities F Forbion (Major Shareholder)
  3. Ronald Harold Wilfred Cooper (CEO)
Learn More about top insider investors at enGene.

Who are the major institutional investors of enGene?

enGene's top institutional shareholders include:
  1. Franklin Resources Inc. — 2.69%
  2. Point72 Asset Management L.P. — 1.50%
  3. Wolverine Asset Management LLC — 0.01%
Learn More about top institutional investors of enGene stock.

Which institutional investors are buying enGene stock?

In the previous quarter, ENGN stock was purchased by institutional investors including:
  1. Point72 Asset Management L.P.
  2. Franklin Resources Inc.
  3. Wolverine Asset Management LLC
Within the previous year, these company insiders have bought enGene stock:
  1. De Solidarite Des Travai Fonds (Major Shareholder)
  2. Growth Opportunities F Forbion (Major Shareholder)
Learn More investors buying enGene stock.